Evidence map›Paper›PMID 41892611›Full record

ArticleBrain sciences2026

Association Between

Alejandra Monserrat Rodríguez-Ramírez, Mariela Benitez-Valenzuela, María Teresa Alcántara-Garcés, Marco Antonio Sanabrais-Jiménez, Julio Uriel Zaragoza-Hoyos, Humberto Del Valle-Ramírez, Viviana Hernandez-Romero, Augusto Rojas-Martínez, Ana Cristina García-Ulloa, Beatriz Camarena-Medellin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alejandra Monserrat Rodríguez-RamírezCentro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.ORCID 0000-0002-9248-0472
Mariela Benitez-ValenzuelaCentro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
María Teresa Alcántara-GarcésCentro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
Marco Antonio Sanabrais-JiménezDepartamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.ORCID 0000-0002-7722-5940
Julio Uriel Zaragoza-HoyosDepartamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.ORCID 0000-0001-9685-6847
Humberto Del Valle-RamírezCentro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
Viviana Hernandez-RomeroDepartamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.
Augusto Rojas-MartínezEscuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.
Ana Cristina García-UlloaCentro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
Beatriz Camarena-MedellinDepartamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.

Funding

Consejo Nacional de Ciencia y Tecnología Mexico 214718
6 · The paper itself

Abstract

introductionMajor depressive disorder (MDD) is a common comorbidity of type 2 diabetes (T2D) with low rates of treatment response to antidepressants. The pathophysiology of these conditions overlaps in N-methyl-d-aspartate receptors (NMDARs), which are present in neurons and pancreatic cells.

objectiveWe aimed to evaluate the association between

methodsA prospective study was conducted on T2D patients enrolled in a comprehensive care program with follow-up at 3 months. Subjects were assessed for MDD, and genotyping for

resultsOur sample included 232 patients; among them, 49 (21%) had MDD. Patients with MDD showed a higher frequency of the AA genotype compared with non-MDD subjects (

conclusionsThe A allele of

Indexed as

affective disordersantidepressantsdiabetespsychiatric genetics

Identifiers

PMID41892611
PMCPMC13023908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.